Written in Blood

Written in Blood

Research from recent issues of Blood

Can Pevonedistat Improve Azacitidine’s Activity in Older Patients With AML?

Adding pevonedistat, a first-in-class inhibitor of the NEDD8-activating enzyme (NAE), to azacitidine led to responses in patients with acute myeloid leukemia (AML), according to...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...
WIB_icon

International Workshop on CLL Updates Guidelines for the Design and Conduct of Clinical Trials

Prompted by advances in the biology and treatment of patients with chronic lymphocytic leukemia (CLL), the National Cancer Institute–sponsored International Workshop on CLL has...
WIB_icon

Insights From a Pyruvate Kinase Deficiency Registry: Broad Spectrum of Severity, Broad Role for...

No guidelines exist for the diagnosis, management, and monitoring of patients with red cell pyruvate kinase (PK) deficiency – the most common glycolytic defect...
WIB_icon

Brentuximab Vedotin and CHP Combination Leads to Lasting Remissions in Peripheral T-Cell Lymphomas

Half of patients with peripheral T-cell lymphomas (PTCLs) who were treated with brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, prednisone) remained in remission...
WIB_icon

The Effect of Moxetumomab Pasudotox on Minimal Residual Disease in Hairy Cell Leukemia

Nearly two-thirds of patients with relapsed/refractory hairy cell leukemia (HCL) who were treated with the anti-CD22 recombinant immunotoxin moxetumomab pasudotox achieved complete remission (CR),...
WIB_icon

First-in-Human Trial Finds Single-Agent, Post-Transplant IL-15 Superagonist Tolerable, Effective

Allogeneic hematopoietic cell transplantation (alloHCT) is primary potentially curative option for certain patients with advanced hematologic malignancies, but disease relapse post-transplant remains a major...
WIB_icon

Five-Year Follow-Up Shows Response to Ibrutinib Deepens Over Time for CLL Patients

Treatment with continuous, single-agent ibrutinib led to durable responses in patients with chronic lymphocytic leukemia (CLL), even among previously untreated patients, patients older than...
WIB_icon

Ibrutinib Plus R-ICE Induces Responses in Patients With Relapsed/Refractory DLBCL

A phase I study found that adding ibrutinib to R-ICE (rituximab, ifosfamide, carboplatin, etoposide) resulted in an overall response rate of 90 percent (range...
WIB_icon

Treatment With Blinatumomab Eradicates MRD in Patients with ALL

More than three-quarters of patients with acute lymphocytic leukemia (ALL) who were in complete remission (CR) following chemotherapy but still had evidence of minimal...
Advertisement

Current Issue

May 2018, Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.